Optimizing Treatment Approaches and Clinical Practice for Relapsed/Refractory Multiple Myeloma

Optimizing Treatment Approaches and Clinical Practice for Relapsed/Refractory Multiple Myeloma is organized by Medical Learning Institute Inc (MLI).

Release Date: Feb 10, 2026
Expiration Date: Feb 9, 2027

Course Details:
Part 1, Evolving Role of Bispecific Antibody Therapy in the Treatment Landscape for RRMM, will explore how bispecific antibody (bsAb) therapies are reshaping the treatment paradigm in RRMM. This white paper reviews the latest clinical evidence, updated guidelines, and expert recommendations to help physicians, NPs, and pharmacists optimize sequencing and overcome resistance. Findings of key clinical trials from ASCO and EHA will also be highlighted. Discover how to integrate bsAbs into treatment plans while maintaining a patient-centered approach through shared decision-making and real-world application.    

Part 2, Leading the Advancement of Health Equity in MM, health equity in RRMM remains an urgent and actionable challenge. This white paper explores disparities in trial enrollment, treatment access, and outcomes—drawing from recent data presented at SOHO 2025 and other leading conferences. Special attention is given to the real-world accessibility of BCMA-targeted therapies and their implications for underserved populations. Learners will gain practical strategies to promote equitable care, including culturally responsive communication and community-driven engagement models that support inclusive, high-quality treatment across all practice settings.   

Part 3, The Evolving Role of Cellular Therapies Treatment-Related Adverse Event Management, will deliver care that aligns with what matters most to your patients. This white paper focuses on patient-reported outcomes (PROs) and provides practical strategies to mitigate treatment-related adverse events (TRAE) associated with novel immunotherapies for RRMM. Based on cutting-edge data from ASH 2025, this resource reviews the latest evidence on cytokine release syndrome (CRS)/neurological toxicity management, long-term TRAE mitigation, and strategies to preserve quality of life (QoL) in diverse patients. Backed by emerging PRO data, clinicians will learn how to maintain treatment benefit while preserving QoL across diverse patient populations.?

Learning Objectives
After completing this activity, the participant should be better able to: 

• Apply the latest clinical evidence on T-cell directed therapies, including bispecific antibodies (bsAbs), based on MoA, administration, indication, efficacy, and safety to optimally select and sequence treatment for patients with RRMM
• Reduce healthcare disparities in RRMM by improving access to clinical trials, enhancing patient-provider communication, and providing education to better support underserved patients throughout the care continuum 
• Mitigate TRAEs and toxicities with bsAbs to improve tolerability and maintain quality of life (QoL) for patients with RRMM 

Agenda
Part 1

• Role of bsAb therapy in the era of T-cell mediated treatments for RRMM 
• Summary of updates to the NCCN recommendations 
• Clinical trial overview of available and emerging therapies (in Ph 2/3) and novel therapeutic targets 
  • Interpreting subgroup analyses of trials that included cohorts with prior BCMA exposure 
  • Select ongoing studies of bsAbs in newly diagnosed MM 
• Strategies for treatment sequencing and potential areas for mechanisms of resistance using T-cell directed therapies 
• Prioritizing shared decision making in treatment selection 
• Include summary tables of trials/ongoing studies  

Part 2

• Heme/onc perspective on conference highlights: How might this change my practice? 
  • Highlights of disparities-focused data: enrollment trends, subgroup analyses, community-partnered research 
• Current state of disparities in RRMM and the latest data  
  • Updated epidemiology and outcomes data in racial, ethnic, rural, and socioeconomically disadvantaged groups 
  • Gaps in access to novel BCMA-directed therapies in real-world populations 
  • New data or initiatives focused on culturally sensitive patient-provider interactions 
• Identify opportunities for heme/onc to engage/initiate strategies to reduce health disparities, including in community settings 
  • Enhancing patient education and empowerment across care settings 
  • Referring to trials, accessing advanced therapies, and supporting QoL in underserved patients 
• Include summary tables of trials/ongoing studies and diverse patient enrollment 

Part 3 

• Heme/onc?perspective on EHA conference highlights: How might this change my practice?? 
• Review of TRAEs and toxicities based on treatment modality? 
  • Summary of evidence of dose reduction, interruption, discontinuation on T-cell mediated therapies? 
• What to expect in managing the potential for long-term toxicities? 
  • Balancing effective therapies in consideration of tolerability to sustain and improve QoL? 
  • Overview of PROs for T-cell directed therapies? 
• Mitigation of toxicities?based on treatment modality? 
• Updates from ASH?